On Tuesday, Canaccord Genuity sustained its optimistic stance on Cibus (NASDAQ:CBUS) shares, reaffirming a Buy rating and a $20.00 price target for the company's shares. The investment firm's analysis suggests that while significant trait royalty revenue for Cibus is anticipated to begin in 2026-2027, the current focus is on successfully deploying its plant gene editing technology on a commercial scale.
The firm highlighted that Cibus's Research and Development (R&D) initiatives and cost reduction plans are strategically designed to support the company's long-term goals. These measures aim to ensure the generation of trait royalties while also preserving cash throughout the near-term R&D phase. This approach is considered crucial given that the expected increase in revenue is projected to commence in approximately three years.
In light of these strategies, Canaccord Genuity has updated its financial model for Cibus, accounting for decreased general and administrative (SG&A) expenses projected for the years 2025 to 2028. Furthermore, the firm has applied a slightly higher discount rate of 21.7% in its analysis.
The company's trajectory is being closely monitored by the investment firm, which emphasizes the importance of the R&D phase in laying the groundwork for future revenue streams. The reiterated Buy rating and price target reflect confidence in Cibus's potential to achieve its long-range financial objectives through the implementation of its innovative technology and prudent financial management.
In other recent news, agricultural technology company Cibus Inc. has announced a series of cost reduction initiatives, including a workforce reduction of 26 employees. These measures are expected to result in approximately $10 million in annual savings and a reduction of cash use by about 20%.
The restructuring aligns with Cibus's strategic shift towards commercializing its gene-editing technology for major crops. Carlo Broos, a seasoned executive with the company since 2011, has been appointed as Interim Chief Financial Officer, following the departure of Wade King.
Cibus also recently announced a public offering of 3,000,000 shares, with Roth Capital Partners and A.G.P./Alliance Global Partners (NYSE:GLP) partially exercising an option to purchase an additional 289,953 shares. This move has brought in extra capital for the company.
These recent developments are part of Cibus's ongoing efforts to streamline operations and concentrate resources on priority objectives.
InvestingPro Insights
While Canaccord Genuity maintains an optimistic outlook on Cibus (NASDAQ:CBUS) with a Buy rating and a $20.00 price target, recent InvestingPro data and tips provide additional context for investors to consider.
InvestingPro data shows that Cibus has experienced significant revenue growth, with a 816.72% increase in the last twelve months as of Q2 2024. This aligns with the company's focus on deploying its plant gene editing technology commercially. However, it's important to note that despite this growth, the company is not yet profitable, with an operating income margin of -2503.38% for the same period.
Two key InvestingPro Tips highlight potential challenges:
1. Cibus is quickly burning through cash, which underscores the importance of the company's cost reduction plans mentioned in the article.
2. The stock price has fallen significantly over the last year, with a one-year price total return of -80.42%.
These insights suggest that while Cibus's long-term strategy may have potential, as indicated by Canaccord Genuity's analysis, the company faces near-term financial pressures that investors should carefully consider.
For a more comprehensive analysis, InvestingPro offers additional tips and data points that could provide further insights into Cibus's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.